GlaxoSmithKline Biologicals SA
www.gsk.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From GlaxoSmithKline Biologicals SA
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.
GSK Seeks To Prevent Pfizer From Selling Its Rival RSV Vaccine In the US
Claiming Pfizer’s Abrysvo infringes four of its patents, GSK asks court to permanently enjoin Pfizer from making or selling the vaccine in the US but would exempt the pending maternal indication.
China In-Licensing Model Still Has Profitable Legs: LianBio CEO
China- and US-based biotech LianBio is advancing three late-stage clinical assets in hopes that successful commercialization could lead to profitability and validate its in-licensing business model in a challenging environment.
Biopharma Industry Sharply Divided Over Supreme Court Antibody Patent Brawl
Big biologic makers line up on opposite sides of dispute between Amgen and Sanofi over whether Amgen’s Repatha patents cover analogous antibodies with the same functional characteristics.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice